We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
+$36.5M
Cap. Flow %
3.32%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Miscellaneous 86.88%
2 Healthcare 12.71%
3 Financials 0.19%
4 Technology 0.09%
5 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
201
DELISTED
Aerie Pharmaceuticals
AERI
– –
-4,726
Closed -$230K
AERI
202
PUT
DELISTED
Aerie Pharmaceuticals
AERI
– –
-74
Closed -$360K
GBT
203
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-301
Closed -$935K
SRRA
204
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-13,339
Closed -$827K
ATRS
205
CALL
DELISTED
Antares Pharma, Inc.
ATRS
– –
-1,016
Closed -$329K
ATRS
206
PUT
DELISTED
Antares Pharma, Inc.
ATRS
– –
-227
Closed -$74K
ADXS
207
DELISTED
Advaxis Inc
ADXS
– –
-2,509
Closed -$127K
ADXS
208
PUT
DELISTED
Advaxis Inc
ADXS
– –
-28
Closed -$173K
FLXN
209
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-341
Closed -$825K
FLXN
210
PUT
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-292
Closed -$706K
KDMN
211
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-525,695
Closed -$1.76M
GWPH
212
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-28,517
Closed -$3.35M
FPRX
213
PUT
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-758
Closed -$3.1M
IMMU
214
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-1,322
Closed -$1.85M
STML
215
CALL
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-802
Closed -$890K
STML
216
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-43,749
Closed -$486K
MDCO
217
CALL
DELISTED
Medicines Co
MDCO
– –
-66
Closed -$244K
VXZ
218
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
– –
-26,500
Closed -$551K
ANTH
219
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-52,046
Closed -$89.6K
RNVA
220
DELISTED
Rennova Health, Inc.
RNVA
– –
-31,125
Closed -$91K
KITE
221
PUT
DELISTED
Kite Pharma, Inc.
KITE
– –
-543
Closed -$9.76M
ROSG
222
DELISTED
Rosetta Genomics Ltd.
ROSG
– –
-141,741
Closed -$149K
ROKA
223
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
– –
-237,322
Closed -$173K
CYTR
224
PUT
DELISTED
CytRx Corp
CYTR
– –
-17
Closed -$4K
RIBT
225
DELISTED
RiceBran Technologies
RIBT
– –
-44,203
Closed -$575K
6 7 8
9
10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management deployed $36.5M of net new capital in Q4 2017, opening 63 new positions and adding to 36 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 92% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $3.2M trimmed.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.